May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Cardiac & Vascular Institute in Florida.

May 4, 2023 — What if you could predict if-or when-your patient might experience a heart attack, cardiac arrest or another heart-related problem? 

A new book written by and for interventional cardiologists provides a collection of detailed case studies, clinical data and imagery, according to Cedars-Sinai, whose team from Smidt Heart Institute is among the editors of the publication.

May 4, 2023 — A new book on a broad collection of cases, led by a team of investigators from the Smidt Heart Institute at Cedars-Sinai (Los Angeles, CA), with other editors and contributors, is now available for interventional cardiologists to consult, according to an April 27 online news summary published by Cedars-Sinai.

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the wealth of technological advancements, bringing the necessary tools together in a streamlined workflow has remained a challenge for clinicians.


 Invented in 1896 by Enrico Salvioni, the fluoroscope remains a flagship technology of modern medicine. The live video X-ray image it provides can guide a catheter safely through a living patient’s circulatory system, delivering a therapeutic action precisely where needed.

May 3, 2023 — A new flexible, wearable medical device could provide a major boost in the fight against heart disease, the leading cause of death in the United States. 

May 3, 2023 — The Society of Cardiovascular Computed Tomography (SCCT) Board of Directors is proud to announce that Martha Gulati, MD, FACC, FAHA, FASPC, FESC has been named the recipient of the 2023 Arthur S. Agatston Cardiovascular Disease Prevention Award for her extensive contributions to the study of women and cardiac diseases and to efforts to improve women’s healthcare. 

May 2, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its second-generation DSR product (DSR 2.0) for th

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now